Display Settings:

Format

Send to:

Choose Destination
    Psychopharmacology (Berl). 2011 Apr;214(4):933-9. Epub 2010 Dec 8.

    Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

    Source

    Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, USA.

    Abstract

    RATIONALE:

    Salvinorin A (SA) is a highly selective kappa opioid receptor agonist and the putative psychoactive compound in Salvia divinorum (SD), an increasingly abused hallucinogenic plant.

    OBJECTIVES:

    The objectives of this study were to characterize the physiological and subjective effects of SA versus placebo and measure drug and metabolite levels.

    METHODS:

    Sublingual SA doses up to 4 mg were administered in dimethyl sulfoxide/polyethylene glycol 400 solution to eight SD-experienced subjects using a placebo-controlled ascending-dose design.

    RESULTS:

    No dose of SA produced significantly greater physiological or subjective effects than placebo. Furthermore, effects did not resemble reported "typical" effects of smoked SD. SA was detectable in plasma and urine, but was, in most cases, below the reliable limit of quantification (0.5 ng/mL).

    CONCLUSIONS:

    Our results suggest that the sublingual bioavailability of SA is low. Higher doses, alternate formulations, or alternate routes of administration will be necessary to study the effects of SA in humans.

    PMID:
    21140258
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3063546
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Fig. 1

      Supplemental Content

      Icon for Springer Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk